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Abstract
Objective. Mutations in the EIF1AX gene have been recently detected in a small percentage of benign and malignant thyroid
lesions. We sought to investigate the prevalence and clinical significance of EIF1AX mutations and co-mutations in cytologically indeterminate thyroid nodules at our institution. Materials and Methods. A 5-year retrospective analysis was performed
on thyroid nodules with a cytologic diagnosis of Bethesda category III or IV, which had undergone testing by our in-house next
generation sequencing panel. Surgically resected nodules with EIF1AX mutations were identified, and mutation type and presence of co-mutations were correlated with histopathologic diagnosis. Results. 41/904 (4.5%) cases overall and 26/229 (11.4%)
surgically resected nodules harbored an EIF1AX mutation. The most common histologic diagnoses were follicular thyroid carcinoma and follicular variant of papillary thyroid carcinoma. 11/26 (42.3%) of nodules had isolated EIF1AX mutation. Comutations were found in RAS (12/26; 46.2%), TERT (5/26; 19.2%) and TP53 (2/26; 7.7%). EIF1AX mutation alone conferred a
36.4% risk of malignancy (ROM) and 54.5% ROM or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), while the ROM was significantly higher in nodules with concurrent RAS (71.4%), TERT, TP53 and RAS+TERT
(100%) mutations. Conclusion. EIF1AX mutations occur in benign and malignant follicular thyroid neoplasms. In our cohort,
the majority of mutations occurred at the splice acceptor site between exons 5 and 6. Importantly, the coexistence of EIF1AX
mutations with other driver pathogenic mutations in RAS, TERT and TP53 conferred a 100% ROM or NIFTP, indicating that
such nodules require surgical removal.
Key Words: EIF1AX  Thyroid Nodule  Cytopathology  Next-Generation Sequencing.

Introduction
Up to 30% of biopsied thyroid nodules are classified as either “atypia of undetermined significance
(AUS)/follicular lesion of undetermined significance (FLUS)” or “follicular neoplasm (FN)/suspicious for follicular neoplasm (SFN)”, Categories
III and IV respectively in The Bethesda System
for Reporting Thyroid Cytopathology (TBSRTC)
(1). Because these diagnoses are not straightforward benign or malignant, and the reported risks
of malignancy are highly variable for these categories, clinicians often struggle with the decision of
whether or not to recommend surgical removal of
these indeterminate nodules. Molecular analysis,
via multi-gene sequencing assays and gene expres4

sion classifiers, has emerged as an important supplemental tool for evaluating thyroid nodules (1,
2). At our institution, thyroid fine needle aspiration (FNA) specimens with an indeterminate cytologic diagnosis are routinely tested via an in-house
next generation sequencing (NGS) panel, in order
to provide clinicians with more information that
may help with risk stratification and guide clinical
management.
The most commonly known mutated genes associated with thyroid malignancies are BRAF and
RAS. The majority of BRAF mutations are found
in classical papillary thyroid carcinoma (PTC),
while RAS mutations are seen in follicular variant of papillary thyroid carcinoma (FVPTC) and
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other malignant and benign follicular-patterned
thyroid lesions (3). More recently, mutations in
the EIF1AX (Eukaryotic translation initiation factor 1A, X-chromosomal) gene have been detected
in a small percentage of various types of thyroid
cancer as well as benign thyroid nodules. The likelihood of malignancy in an EIF1AX-mutated thyroid nodule is thought to correlate with the presence or absence of co-existing mutations and with
the position of the mutations within EIF1AX (4).
We sought to investigate the prevalence and
clinical significance of EIF1AX mutations and comutations by examining histologic outcomes of a
large cohort of cytologically indeterminate thyroid
nodules that underwent molecular testing and
subsequent surgical resection.

Materials and Methods

antPlex Assay for Illumina Platform (ArcherDx)
following the manufacturer’s protocol. Besides EIF1AX both TruSeq and Archer panels contained
primers to amplify targeted regions of interest
covering hotspots from additional thyroid cancerrelated genes such as BRAF, GNAS, HRAS, NRAS,
PIK3CA, PTEN, RET, TERTpro, TP53 and TSHR.
Libraries were sequenced on the Illumina MiSeq
or NextSeq 500 instrument with paired end 150-bp
sequencing. Data analysis was performed as previously described (5) for all TruSeq libraries. For all
libraries prepared using Archer VariantPlex methodology, fastq files were generated using a custom
script and data analyses were performed using the
CTL target region file and Archer analysis software
version 6.2. Annotated variants were filtered and
reported using an in-house, Web-based reporting
application ClinMutReporter (Thomas Jefferson
University Hospitals, Philadelphia, Pennsylvania).

Case Selection and Histopathologic Correlation
A database search was performed to identify
all thyroid nodules with a cytologic diagnosis of
Bethesda category III or IV, which had undergone
testing by our in-house NGS panel over a 5-year
period. Samples with EIF1AX mutations were
identified, and the electronic medical record was
searched to determine which nodules had undergone surgical resection. EIF1AX mutation type
and presence of co-mutations were correlated with
final histopathologic diagnosis.

Results

Molecular Specimen Information

Clinical & Pathologic Features

At the time of the FNA procedure, a separate needle pass was collected in a vial containing methanol/acetic acid (3:1 ratio). Of the 987 clinical FNA
specimens, 904 (91.6%) passed sample quality
control and obtained molecular results.

The clinical and pathologic features of the 26 patients with full diagnostic characterization are
shown in Table 1. The mean patient age was 64
(range: 43-81 years) and with a female preponderance (female:male ratio=3.3). The mean size of the
nodules was 2.8 cm (range: 1.1-6.3 cm). The cytopathologic diagnosis was Bethesda Category III
(AUS/FLUS) in 12 (46.2%) and Bethesda Category
IV (SFN/FN) in 14 (53.8%). As shown in Table 1
and Figure 1, the histopathologic analysis on follow up excisions included 6 neoplasms with a benign diagnosis (follicular adenoma (FA)), 3 with

Molecular Analysis
Mutations in EIF1AX were identified by NGS with
a custom designed Thyroid cancer panel using Illumina’s TruSeq Custom Amplicon version 1.5
reagents as previously described (5) or CTL Vari-

Patients
Among the 904 thyroid FNAs with an indeterminate cytopathologic diagnosis (Bethesda Category III or IV) that were characterized by NGS, 41
cases (4.5%) had mutations in the EIF1AX gene.
Histopathologic confirmation of the diagnosis was
available in a surgical follow up specimen in 26 of
the 41 cases (63.4%).
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Table 1. Summary of All EIF1AX-Mutated Surgically Removed Nodules
Case

Age
(y)

1

63

Gender

Nodule
size (cm)

Cytologic
diagnosis
(Bethesda
category)

Histopathologic
EIF1AX mutation type
diagnosis

Alternate
allele
frequency
(AAF)

EIF1AX mutation
location

EIF1AX
mutation
significance

Co-existing
mutation(s),
AAF

F

1.4

3

FA

26.6%

Exon 6

Unknown

KRAS
p.A59del, 5.6%

c.370_371delinsTT; p.G124L

2

56

F

4.1

3

FA

c.338-1_338delinsTT; p.?

3.3%

A113_splice site

Pathogenic

-

3

43

F

1.1

3

FA

c.16G>C; p.G6R

9.7%

N terminus

Pathogenic

-

4

75

M

2.7

4

FA

c.338-2A>C; p.?

7.1%

A113_ splice site

Pathogenic

-

5

66

F

2.5

4

FA

c.44G>A; p.G15D

9.7%

N terminus

Pathogenic

-

6

63

F

2.6

4 (Hurthle
cell type)

FA

c.338-2A>T; p.?

14.1%

A113_ splice site

Pathogenic

-

7

76

F

5.2

3

NIFTP

c.338-4_355del; p.?

16.5%

A113_ splice site

Pathogenic

-

8

70

F

1.1

4

NIFTP

c.5C>G; p.P2R

4.6%

N terminus

Pathogenic

-

9

59

F

1.5

4

NIFTP

c.210G>C; p.W70C

40.0%

Exon 4

Likely
pathogenic

NRAS p.Q61K,
41.9%

10

51

M

1.8

3

FTC

c.338-1G>C; p.?

19.5%

A113_ splice site

Pathogenic

KRAS p.Q61R,
8.7%

11

54

F

1.5

3

FTC

c.338-1G>C; p.?

35.2%

A113_ splice site

Pathogenic

NRAS p.Q61R,
39.2%; TERT c.146C>T, 39.7%

12

46

F

2.3

3

FTC

c.3_5dup; p.P2dup

4.2%

N terminus

Likely
pathogenic

TERT c.146C>T, 7.3%

13

69

F

2.2

3

FTC

c.28A>G; p.K10E

31.2%

N terminus

Pathogenic

14

71

M

5.5

4

FTC

c.338-2A>G; p.?

40.6%

A113_ splice site

Pathogenic

HRAS p.Q61R,
20.3%; TERT c.124C>T, 11.4%

15

57

F

3

4

FTC

c.338-1G>C; p.?

2.1%

A113_ splice site

Pathogenic

NRAS p.Q61K,
2.4%

16

60

F

6.3

4

FTC

c.338-2A>T; p.?

12.7%

A113_ splice site

Pathogenic

KRAS p.Q61R,
12.8%; TERT c.124C>T, 15.1%

17

69

F

3

4 (Hurthle
cell type)

HCC

c.338-1G>C; p.?

26.6%

A113_ splice site

Pathogenic

-

18

81

M

3.7

4 (Hurthle
cell type)

HCC

c.338-1G>A; p.?

19.1%

A113_ splice site

Pathogenic

-

19

71

F

3.5

4 (Hurthle
cell type)

HCC

c.338-1G>T; p.?

40.3%

A113_ splice site

Pathogenic

TP53 p.H179R,
66.4%

20

63

M

3.1

3

EFVPTC

c.429+1G>A; p.?

39.5%

D143_splice site

Likely
pathogenic

-

21

59

F

1.8

3

EFVPTC

c.338-1_339delinsACA; p.?

6.7%

A113_ splice site

Pathogenic

NRAS p.Q61K,
8.2%

22

68

F

1.3

3

EFVPTC

c.338-2A>T; p.?

4.5%

A113_ splice site

Pathogenic

NRAS p.Q61R,
4.3%

23

58

M

4.5

4

EFVPTC

c.338-2A>T; p.?

23.50%

A113_ splice site

Pathogenic

HRAS p.Q61R,
12.7%; TP53
p.Q331Rfs*14,
10.1% &
p.S240R, 10.9%

24

65

F

2.7

4

EFVPTC

c.26G>T; p.G9V

22.2%

N terminus

Pathogenic

NRAS p.Q61R,
28.9%

25

68

F

2.6

3

IFVPTC

c.338-8_338-1del; p.?

26.3%

A113_ splice site

Pathogenic

HRAS p.Q61R,
25.5%; TERT c.124C>T, 21.6%

26

74

F

1.5

4

IFVPTC

c.338-1G>C; p.?

16.7%

A113_ splice site

Pathogenic

YWHAG-BRAF
Fusion

EFVPTC=Encapsulated follicular variant of papillary thyroid carcinoma; F=Female, FA=Follicular adenoma, FTC=Follicular thyroid carcinoma; HCC=Hurthle
cell carcinoma; IFVPTC=Infiltrative follicular variant of papillary thyroid carcinoma; M=Male, NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like
nuclear features.
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Molecular Characterization

FA=Follicular adenoma; FTC=Follicular thyroid carcinoma; FVPTC=Follicular
variant of papillary thyroid carcinoma; HCC=Hurthle cell carcinoma;
NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear
features.

Figure 1. Prevalence of histopathologic diagnoses
in surgically resected EIF1AX-mutated cytologically
indeterminate thyroid nodules (N=26).

a noninvasive follicular thyroid neoplasm with
papillary-like nuclear features (NIFTP) diagnosis
and 17 with a malignant diagnosis.
Malignant neoplasms included follicular thyroid carcinoma (FTC) (N=7), encapsulated follicular variant of papillary thyroid carcinoma
(EFVPTC) with capsular invasion (N=5), Hurthle
cell carcinoma (HCC) (N=3), and infiltrative follicular variant of papillary thyroid carcinoma (IFVPTC) (N=2). The Bethesda Category III and IV
cytopathologic diagnoses did not distinguish between benign and malignant thyroid neoplasms,
as shown in Table 1.

These 26 cases were characterized by mutations in
the EIF1AX gene. Two distinct types of mutations
were observed, as shown in Figure 2 and Table 1.
A mutation at the 3’ end of the exon 6 splice site
was observed in 17 cases and missense mutations
in the N-terminal of the protein containing basic
amino acids was present in 5 cases. In 4 patients
the mutations did not fit neatly into this distribution. A duplication of the proline residue encoded
by codon 2 was also detected, but it differs from
the missense mutations more commonly seen in
the N-terminal. In addition, the p.W70C mutation occurs in a “mini-cluster” of mutations that
have been seen in non-thyroid malignancies, but
have not been reported in thyroid neoplasia in
the COSMIC (6) or cBioPortal (7) databases. The
p.G124L and c.429+1G>A mutations have not
been previously reported in thyroid malignancies.
Single mutations in the exon 6 splice site or the
basic amino terminal tail occurred in both benign
and malignant thyroid neoplasms. In addition to
the abnormal EIF1AX gene, mutations in significant tumor-associated genes occurred in 15 of the
26 cases, and 13 of the 15 were detected in malignant neoplasms. The additional mutated genes,
shown in Table 1, included NRAS (N=6), HRAS
(N=3), KRAS (N=3), the common TERT promoter
mutation (N=5), and TP53 (N=2). In 4 cases the
TERT promoter mutation occurred with a RAS
gene mutation and in one patient a TP53 mutation
occurred with a mutant RAS gene. One case also
harbored a novel YWHAG-BRAF fusion.
EIF1AX mutation alone conferred a 36.4%
(4/11) risk of malignancy (ROM) and 54.5% (6/11)
risk of malignancy or NIFTP, while ROM was significantly higher in nodules with concurrent RAS
(71.4%; 5/7), TERT, TP53 and RAS+TERT (100%)
mutations (Table 2).
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X-axis shows the number of mutations. Green and black circles denote missense and splice site mutations respectively.

Figure 2. Distribution of EIF1AX mutations in surgically resected thyroid nodules (N=26)
Table 2. Summary of Risk of Malignancy (ROM) for All EIF1AX-Mutated Surgically Removed Nodules
Mutation(s)

Number
of cases

Percentage

ROM
(%)

ROM or
NIFTP (%)

EIF1AX alone

11

42.3

36.4

54.5

EIF1AX + RAS

7

26.9

71.4

85.7

EIF1AX + RAS + TERT

4

15.4

100

100

EIF1AX + RAS + TP53

1

3.8

100

100

EIF1AX + BRAF Fusion

1

3.8

100

100

EIF1AX + TERT

1

3.8

100

100

EIF1AX + TP53

1

3.8

100

100

Overall

26

100

65.4

76.9

ROM=Risk of malignancy; NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Discussion
EIF1AX encodes the essential, ubiquitously-expressed eukaryotic translation initiation factor
EIF1A with 144 amino acids. As a part of the 43S
pre-initiation complex (PIC), it binds to the capped
mRNA, aids in localizing the start codon and initiates translation. EIF1A protein contains a core
RNA binding domain spanning the residues 32-95
which is flanked on either side by highly charged
unstructured N- and C-terminus tails (8). Originally identified in uveal melanomas, EIF1AX mutations have now also been detected in a variety of
other tumor types, including low-grade gliomas,
lung adenocarcinoma, endometrial carcinoma,
and various neoplastic and nonneoplastic thyroid
lesions (4, 9-11). Missense mutations of the first
2-15 amino acids at the N-terminus of EIFIAX
have been identified in several cancers (9, 12-14).
An additional hotspot splice-site mutation (A113_
splice) in the C-terminus of the protein is thought
to be exclusive to thyroid carcinoma (9, 11, 15).
8

In our study, 4.5% of cytologically indeterminate thyroid nodules (41 out of 904 total cases)
and 11.4% (26 out of 229) of those that were surgically resected harbored an EIF1AX mutation. Of
these cases, the histopathologic diagnoses were
benign neoplasm (FA) in 6/26 (23.1%), NIFTP
in 3/26 (11.5%) and malignant neoplasm (FTC,
HCC or FVPTC) in 17/26 (65.4%) (Table 3A). Karunamurthy et al. (4) found EIF1AX mutations in
27/647 (4.2%) of indeterminate cytology samples,
of which 5 had surgical follow-up information (1
EFVPTC, 1 hyperplastic nodule (HN), and 3 FA)
yielding an estimated ROM of 20%. Our overall
ROM is much higher (65.4%), and even in our
nodules with EIF1AX mutation alone and no other coexisting mutations, the ROM is 36.4% (4/11)
and ROM/NIFTP is 54.5% (6/11) (Table 2). All of
our nodules were neoplastic, though other studies have found mutations in one case of HN (4).
Of note, the estimated ROM calculated in studies
such as this one are overestimations of the actual

Stacey M. Gargano et al: EIF1AX Mutations in Indeterminate Thyroid Nodules

ROM, due to the impact of selection bias. Nodules
that undergo surgical resection are more likely to
have suspicious pre-operative clinical findings (e.g.
worrisome radiologic features, interval growth),
increasing the likelihood of malignancy regardless
of the FNA diagnosis and molecular result.
Similar to other studies, the most common
type of EIF1AX mutation identified in our study
was the A113_splice mutation at the intron 5/exon
6 splice site of EIF1AX (17/26), followed by the
missense mutations in N-terminus of the protein
(5/26). Previous studies have concluded that the
A113_splice mutation, especially with co-existing
RAS mutation, is more frequently observed in thyroid cancer than isolated EIF1AX mutations or
mutations at the N-terminus hotspot of the gene
(4, 11, 14). In our study, 13/17 (76.5%) surgically
resected nodules with the A113_splice mutation
and 3/5 (60%) nodules with an N-terminal missense mutation were malignant. Of the 13 malignant nodules with the A113_splice mutation, 10
harbored co-mutations (5 harbored one co-mutation and 5 harbored two co-mutations). Of the 3
malignant nodules with N-terminus mutation, 2
harbored co-mutations. Please refer to Table 1 for
details.
Four cases harbored EIF1AX mutations that
did not belong to the 2 common types discussed
above. The N-terminal duplication (c.3_5dup,
p.P2dup) was not in the COSMIC database, but
is likely similar to the missense mutations in the
same region. The EIF1AX p.W70C identified in the
NIFTP case had a concurrent RAS mutation. In
the COSMIC database, 4 cases with this mutation
and 3 additional missense mutations at this amino
acid position had been reported in non-thyroid
cancer specimens, which makes the p.W70C mutation likely pathogenic. The mutation p. G124L
(c.370_371delinsTT), detected in a FA, has been
reported once in the COSMIC database, in a small
cell carcinoma of the lung. Mutations affecting
the same amino acid, p.G124* and p.G124V, were
reported in a single thyroid carcinoma specimen
(cBioPortal, sample ID TCGA-EM-A3ST-01).
Lastly, the mutation c.429+1G>A, exon 6/intron 6 splice site mutation, detected in one of our

EFVPTC cases, has never been reported, but 7 malignant cases with mutations affecting the D143_
splice site were documented in the COSMIC database. This mutation most likely affects splicing and
hence the function of the protein.
Other studies have reported EIF1AX mutations
co-occurring with several other driver mutations.
Karunamurthy et al. (4) found co-mutations in
3/11 cases (2 with NRAS and 1 with NRAS, TP53
and TERT), all of which were malignant neoplasms. The TCGA study found co-mutations
(KRAS and BRAF) in one of their 6 cases of EIF1AX-mutated PTC (9). Our study showed that
EIF1AX mutations can co-occur with mutations
in RAS, TP53 and TERT promoter (TERTp), and
these co-mutations are associated with a very high
ROM. Co-existing EIF1AX and a hotspot RAS
mutation conferred an 85.7% ROM and 100%
ROM or NIFTP, compared to EIF1AX mutation
alone that conferred a 36.4% ROM. Malignancy
risk was 100% for nodules containing co-mutations in TERTp, TP53, RAS+TERTp, and BRAF fusion. Clinicians must be aware of this and should
strongly consider surgical intervention, at least a
lobectomy, for patients with multiple such mutations in a thyroid nodule.
Key published studies on the EIF1AX mutations in thyroid nodules/cancer specimens are
summarized in Table 3. The histopathologic diagnoses and ROM for EIF1AX mutation positive
specimens identified from FNA with indeterminate cytology (Bethesda III and V), including our
current study, are shown in Table 3A. The frequencies of the EIF1AX mutations in different categories of thyroid nodules from surgically resected
specimens are presented in Table 3B.
While EIF1AX mutations were identified in
HN, FA, and differentiated thyroid cancer (PTC
and FTC), the percentage of specimens containing
the EIF1AX mutations was enriched in advanced
thyroid cancer. By combining the case numbers of
the studies listed in Table 3B, there were 11 positive specimens for EIF1AX mutations in 97 PDTC
(11.3%) and 9 positive in 97 ATC cases (9.3%).
Additional co-existing mutations in PDTC and
ATC include RAS, RAF, TERTp, TP53 mutations.
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Table 3. Prevalence of EIF1AX Mutations in A) Fine Needle Aspirates (FNA) and B) Surgically Removed Nodules, in Present
and Previously Published Studies
A. Characterization of EIF1AX Mutation-Positive Fine Needle Aspirates (FNA) with Indeterminate Cytology

Study

EIF1AXmutated FNA

Surgical pathology follow-up of EIF1AX-mutated FNA
Total
cases

HN

FA

NIFTP

PTC

Karunamurthy
et al, 2016 (4)

27/647; 4.2%

5/27

1/5; 20%

3/5; 60%

-

1/5; 20%

Present Study

41/904; 4.5%

26/41

-

6/26; 23.1%

3/26; 11.5%

7/26; 26.9% (FVPTC)

FTC

HCC

-

-

7/26; 26.9%

3/26; 11.5%

B. Frequency of EIF1AX Mutations in Surgically Removed Nodules
Study

HN

FA

TCGA, 2014 (9)

-

Kunstman et al, 2015 (16)

Differentiated TC

Undifferentiated TC

PTC

FTC

PDTC

ATC

-

6/402; 1.5% (5 FVPTC; 1 mix of
follicular & classical variant)

-

-

-

-

-

-

-

-

3/22; 13.6%

Karunamurthy et al, 2016 (4)

1/80; 1.3%

2/27; 7.4%

2/86; 2.3%

0/53; 0%

0/4; 0%

1/4; 25%

Landa et al, 2016 (11)

-

-

-

-

9/84; 11%

3/33; 9%

Nicolson et al, 2018 (17)

-

-

-

2/39 ; 5.1%

-

-

Pozdeyev et al, 2018 (15)*

-

-

1/89; 1.1%

2/5; 40%

-

2/31; 6.5%

Simoes-Pereira et al, 2019 (14)†

0/7; 0%

-

1/12; 8.3% (FVPTC)

2/9; 22.2%

0/7; 0%

ATC=Anaplastic thyroid cancer; FA=follicular adenoma; FTC=Follicular thyroid carcinoma; HCC=Hurthle cell carcinoma; HN=Hyperplastic nodule;
NIFTP=Noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PDTC=Poorly differentiated thyroid carcinoma; PTC=Papillary thyroid carcinoma; TC=Thyroid cancer; *Only those specimens that were sequenced on MSK-IMPACT panels were included in this table since EIF1AX is not tested by the
FoundationOne Panels; †9 surgical specimens in this study had distinct histological type and were counted separately based on the histology. Please see the
study by Simoes-Pereira et al. (14) for details.

Krishnamoorthy et al. (18) demonstrated EIF1AX
A113_splice mutation increases protein synthesis
globally and cooperates with RAS mutations to increase the stability of c-MYC protein to drive thyroid tumorigenesis.
Among the 26 cases carrying the EIF1AX mutations in our cohort, 11 cases had EIF1AX mutations alone and 15 had co-existing mutations
detected by our NGS panel. Within the 15 comutation cases, 13 were in the RAS/RAF pathway
(including 1 case with a non-hotspot KRAS mutation, p.A59del with unknown significance), and 2
cases had a mutation either in the TERT promoter
or the TP53 gene. When we compared the alternate allele frequencies (AAF) of the EIF1AX and
other co-existing mutations, the AAFs for the EIF1AX mutations were greater than (N=4) or similar to (N=10) that of other driver mutations (Table
1). In the case with a co-existing TP53 mutation,
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the AAF for the TP53 mutation was 66% and AAF
for the EIF1AX mutation was 40%. The apparent
higher AAF of TP53 is likely due to a loss of heterozygosity (LOH) event in this case, given the
AAF of TP53 was well over 50%. The high AAFs of
EIF1AX mutations in comparison to that of co-existing mutations suggests that EIF1AX mutations
represent an early event, at least in some cases, that
promotes initiation of the thyroid tumors and malignant transformation.

Conclusion
EIF1AX mutations can occur in both benign and
malignant thyroid neoplasms. The type of EIF1AX
mutation, and even more importantly, the presence or absence of co-mutations, has an impact on
the likelihood of malignancy in an EIF1AX-mutat-

Stacey M. Gargano et al: EIF1AX Mutations in Indeterminate Thyroid Nodules

ed thyroid nodule. Therefore, in the face of a cytologically indeterminate thyroid nodule with an
EIF1AX mutation detected upon molecular analysis, a more detailed look at the molecular profile,
in conjunction with the clinical and imaging findings, may be helpful in predicting malignancy risk
and determining optimal patient care.
What Is Already Known on This Topic:

EIF1AX mutations occur in wide variety of thyroid lesions, including
HN, FA, NIFTP, well differentiated carcinomas (FTC and FVPTC) and
poorly differentiated carcinomas (PDTC and ATC). Previous studies
examining surgically resected nodules have concluded that the A113_
splice mutation, especially with co-existing RAS mutation, is more frequently observed in thyroid cancer than are isolated EIF1AX mutations
or mutations at the N-terminus hotspot of the gene. However, there
is limited data characterizing EIF1AX mutations in cytology samples
from indeterminate thyroid nodules.

What This Study Adds:

The ROM in an EIF1AX-mutated, cytologically indeterminate thyroid
nodule may be higher than previously reported, for in our study, 36.4%
of thyroid nodules with isolated EIF1AX mutation identified in the FNA
sample were diagnosed as malignant neoplasms upon surgical removal.
Furthermore, our data suggests that the presence of co-mutations, regardless of the position of the EIF1AX mutation, has a significant influence on malignancy risk. The coexistence of EIF1AX mutations with
other pathogenic driver mutations in RAS, TERT and TP53 conferred a
100% ROM or NIFTP in our cohort, indicating that such nodules warrant surgical resection.
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